Present preliminary clinical data from KOMET-007 Phase 1b trial in first-line intensive AML
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Feb 2025
- Due
- 30 Jun 2025
- Delivered
- 12 Jun 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Present preliminary clinical data from KOMET-007 Phase 1b trial in 1L intensive AML 2Q 2025”
What we found
Evidence strength B What the grades mean
Kura Oncology presented preliminary/updated KOMET-007 Phase 1b data for ziftomenib plus 7+3 in frontline AML at EHA on June 12, 2025, within the 2Q 2025 deadline.
-
B Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 EHA Congress Confirms data actually presented at EHA on June 12, 2025
-
B Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 EHA Congress Confirms abstract accepted for oral presentation June 12, 2025
-
D Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data Primary press release confirming presentation date and data details
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Present
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Kura Oncology, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-KURA-000253 · Corrections policy